Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda in post-remission AML patients ≥ 60
NCT02708641Phase 2Completed
- Start
- Oct 2016
- Primary completion
- Jun 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in acute myeloid leukemia (AML). Primary endpoints: Time to Relapse at 24 months and Worst Grade of Adverse Events Experienced at 24 months. Started Oct 2016; status: completed.
02
Drugs
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02708641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02708641.